Skip to main content
. 2022 Aug 22;10(5):e01034-22. doi: 10.1128/spectrum.01034-22

FIG 6.

FIG 6

Correlation between pseudotyped-virus neutralization assay and BLI assay for tixagevimab and cilgavimab and for tixagevimab Fab and cilgavimab Fab. BLI, biolayer interferometry; Fab, antibody fragment; IC50, 50% inhibitory concentration; KD, equilibrium dissociation constant; kd, dissociation constant.